5-甲基-3-苯基-4,5-二氢-异噁唑-5-羧酸 | 842954-77-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-甲基-3-苯基-4,5-二氢-异噁唑-5-羧酸
• 英文名称: 5-methyl-3-phenyl-Δ²-isoxazoline-5-carboxylic acid
• 英文别名: 5-methyl-3-phenyl-4,5-dihydro-isoxazole-5-carboxylic acid；5-Methyl-3-phenyl-4,5-dihydro-isoxazol-5-carbonsaeure；5-methyl-3-phenyl-4,5-dihydro-isoxazole-4-carboxylic acid；5-methyl-3-phenyl-4,5-dihydro-5-isoxazolecarboxylic acid；5-Methyl-3-phenyl-4,5-dihydroisoxazole-5-carboxylic acid；5-methyl-3-phenyl-4H-1,2-oxazole-5-carboxylic acid
• CAS: 842954-77-2
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.213
• InChiKey: HHSXXVCKNAZBGR-UHFFFAOYSA-N

物化性质

• 熔点：
  109-110 °C
• 沸点：
  356.4±52.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-甲基-3-苯基-4,5-二氢-异噁唑-5-羧酸 在 N-甲基吗啉 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[(5-methyl-3-phenyl-4,5-dihydro-isoxazole-5-carbonyl)-amino]-propionic acid
  参考文献：
  名称：

  Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists

  摘要：

  A novel set of compounds containing a 4,5-dihydro-5-methylisoxazoline have been successfully designed as VLA-4 receptor antagonists. Compound (14p) had a high receptor binding affinity of 4 nM and also found to be metabolically stable in vitro. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.043
• 作为产物：
  描述：

  5-methyl-3-phenyl-4,5-dihydro-isoxazole-4-carboxylic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.0h， 生成 5-甲基-3-苯基-4,5-二氢-异噁唑-5-羧酸
  参考文献：
  名称：

  WO2006/90234

  摘要：

  公开号：

文献信息

• [EN] CASPASE INHIBITORS CONTAINING ISOXAZOLINE RING<br/>[FR] INHIBITEURS DE CASPASES CONTENANT UN CYCLE ISOXAZOLINIQUE
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005021516A1

  公开（公告）日：2005-03-10

  The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same

  本发明涉及一种异噁唑啉衍生物，作为对抗各种半胱天冬氨酸蛋白酶的抑制剂，以及制备该异噁唑啉衍生物的方法和包含该异噁唑啉衍生物的用于预防炎症和细胞凋亡的治疗组合物。
• [EN] TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS<br/>[FR] TÉTRAHYDROISOQUINOLINES COMPRENANT DES AZOLES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014160668A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物，或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Caspase inhibitors containing isoxazoline ring
  申请人：Chang Hye-Kyung

  公开号：US20060223848A1

  公开（公告）日：2006-10-05

  The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same

  本发明涉及一种异噁唑啉衍生物作为对各种半胱天冬氨酸蛋白酶的抑制剂，其制备方法，以及包含该异噁唑啉衍生物的治疗组合物，用于预防炎症和细胞凋亡。
• Quilico et al., Gazzetta Chimica Italiana, 1950, vol. 80, p. 479,493
  作者：Quilico et al.

  DOI：——

  日期：——
• Synthesis of functionalized 2-isoxazolines as three-dimensional fragments for fragment-based drug discovery
  作者：Ngoc Chau Tran、Heleen Dhondt、Marion Flipo、Benoit Deprez、Nicolas Willand

  DOI：10.1016/j.tetlet.2015.05.035

  日期：2015.7

  The design of new sp(3) and spiro-enriched fragments has been achieved from 1,3-dipolar cycloaddition between alkenes and chloro-oximes. The selection of reagents was performed to afford a panel of 2-isoxazoline-containing fragments that show desirable three dimensional (3D) characteristics to allow the probing of biologically-relevant chemical space. Principal moments of inertia (PMI) were calculated to evaluate the 3D diversity. The resulting 3D fragments with suitable physicochemical properties, especially a good solubility, will be used to improve the hit rate of our fragment-based screening. (C) 2015 Elsevier Ltd. All rights reserved.